Turkey's pharmaceutical market was valued at approximately USD 10.5 billion in 2025, projected to reach roughly USD 15.6 billion by 2035 at a 4.0% CAGR (IMARC Group); other estimates put the current market closer to USD 12 billion. The market is regulated by TITCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu), which approved 225 new drugs in 2023, including 8 biosimilars. Turkey's pharmaceutical sector includes 300+ local manufacturers and 50+ multinational subsidiaries; leading local players include Abdi İbrahim, Eczacıbaşı, Bilim İlaç, Sanovel, and Deva Holding, alongside multinational subsidiaries such as Novartis Türkiye, Sanofi Türkiye, Pfizer Türkiye, Bayer Türkiye, and Roche Group.
For BioNixus's broader Turkey healthcare and devices coverage, see the Turkey Healthcare Market Report and the Turkey Medical Devices Market Report. This piece focuses specifically on the pharmaceutical market, TITCK registration, and the company landscape.
Market size and growth
IMARC Group values Turkey's pharmaceutical market at approximately USD 10.5 billion in 2025, projecting growth to roughly USD 15.6 billion by 2035 at a 4.0% CAGR. Other third-party estimates put the current market closer to USD 12 billion — a reasonably consistent range across sources, without the wide methodology-driven spread seen in some other emerging pharma markets. Turkey's position as a bridge market between the GCC report cluster and EU5 pricing dynamics — discussed further below — is a structural factor behind this steady growth trajectory.
How TITCK drug registration works
TITCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu — the Turkish Medicines and Medical Devices Agency) governs pharmaceutical registration in Turkey. Key elements of the process:
- CTD dossier format — Turkey mandates the Common Technical Document (CTD) format, aligned with International Council for Harmonisation (ICH) standards, with module requirements varying by application type (new drug vs. abbreviated formats such as generics, hybrids, or biosimilars).
- Electronic submission via OAS — All submissions go through TITCK's Online Application System (OAS), requiring a signed electronic submission agreement and processed fees prior to dossier filing.
- Dossier validation — The formal start of the registration process is dossier validation: a review of the submitted dossier's format and content.
- Required documentation — Scientific data, administrative documents establishing the applicant's legal status, and a GMP certificate must be included in the appropriate CTD modules.
- Reference pricing — TITCK's pricing review references drug prices in five countries: Portugal, Spain, France, Italy, and Greece.
TITCK approved 225 new drugs in 2023, including 8 biosimilars — a useful recent-activity benchmark for approval volumes and biosimilar momentum in the market.
Top pharmaceutical companies in Turkey
Turkey's pharmaceutical sector includes 300+ local manufacturers and 50+ multinational subsidiaries. Leading companies include:
- Abdi İbrahim — one of Turkey's largest local manufacturers, operating AbdiBio, described as one of the country's largest biotech manufacturing investments, targeting monoclonal antibody production
- Eczacıbaşı — major local pharmaceutical and healthcare group
- Bilim İlaç — leading local generics and branded pharmaceutical manufacturer
- Sanovel — major local pharmaceutical manufacturer
- Deva Holding — local pharmaceutical manufacturer with API and finished-dose production
- Novartis Türkiye — multinational subsidiary
- Sanofi Türkiye — multinational subsidiary
- Pfizer Türkiye — multinational subsidiary
- Bayer Türkiye — multinational subsidiary
- Roche Group — multinational subsidiary
This reflects the leading companies active in the Turkish pharmaceutical market rather than a single definitive ranked top-N — no one authoritative ranking source covers the full market, so treat this as a directory of major players rather than a scored ranking.
What this means for market entry
Turkey's General Health Insurance system (SGK) covers approximately 98% of the population, making SGK reimbursement strategy central to any Turkey pharmaceutical launch. Combined with TITCK's five-country reference-pricing basket (Portugal, Spain, France, Italy, Greece), companies planning a Turkey launch need to sequence pricing decisions against those EU5-adjacent markets from the outset rather than treating Turkey pricing as an isolated decision. BioNixus positions Turkey research alongside its wider GCC pharmaceutical market coverage, treating Turkey as a bridge market between Gulf launch sequencing and EU5 reference-pricing dynamics.
For BioNixus's Turkey-specific healthcare and devices intelligence, see the Turkey healthcare market research hub, the Turkey Healthcare Market Report, and the Turkey Medical Devices Market Report. To scope a Turkey market-entry or SGK access strategy programme, request a proposal.
